Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

The Ministry of Public Health and the Lebanese Pediatric Society urge parents to get their Children Vaccinated against Measles

 
WHO and UNICEF call for collective actions to fight measles during outbreak
 
 
February 17, 2020 – The recent measles vaccination campaign launched back in December following the outbreak that has spread across Lebanon have many parents concerned. The Ministry of Public Health, along with the Lebanese Pediatric Society, WHO and UNICEF are very concerned about certain misconstrued comments expressed over the last few weeks by parents on social media and WhatsApp messages. These comments are found to be wrong and misleading, while the only way to protect the child against measles is the vaccination.
 
Since onset in early 2018, the measles outbreak has spread to all eight Lebanese governorates, counting more than 2,000 reported cases, most prominently among children less than 10 years of age.
 
“Choosing to not vaccinate your children during the campaign not only leaves them susceptible to measles, but also exposes other children to measles,” said Dr. Walid Amar, Director General of the Ministry of Public Health. “The Ministry of Public Health, with the support of the World Health Organization and UNICEF, provides safe and effective vaccines free of charge to children through trained teams of health workers in all institutions. We urge all parents to take advice from health professionals on health issues because health policies and practices are evidenced based and not based on rumors”.
 
Measles is a serious and highly contagious disease. If not prevented, measles can cause serious complications including meningitis, severe diarrhea and dehydration, pneumonia and ear infections and even death. Measles survivors are often left with life-long disabilities, such as blindness, deafness and brain damage.
 
“It is important to vaccinate your children during the campaign. The third additional dose of the measles containing vaccine is crucial for optimal immunity and it is safe,” explained Dr. Bizri, Head of National Certification Committee (NCC).  “The cold chain at the MoPH Central Drugs Warehouse and the primary health care facilities are of optimal quality and ensure safe storage of vaccines. Finally, it is important to note that MoPH provides free vaccines to some major private sector health facilities”.
 
“The measles vaccine is safe and effective.  A child to be better protected needs to receive at least two doses of Measles, and there is no harm in receiving an additional dose. There are no reasons children should still be dying of this disease,” added Dr. Majdalani, Head of Lebanese pediatric society.
 
“Immunizations can save a child’s life and vaccines are only given to children after a long and careful review by scientists, doctors, and healthcare professionals. The only way to halt the epidemic currently is to vaccinate all children, between the age of 6 months and 10 years. The Measles vaccine protects children against avoidable lifelong complications and potentially death. No child should be left behind” said Dr Shankiti, representative of WHO office in Lebanon
 
The measles vaccine is procured by UNICEF through its Global Supply Division who is responsible for buying all vaccines and related items for global campaigns to eradicate polio, eliminate neonatal and maternal tetanus, and control measles. All vaccines procured through UNICEF are WHO pre-qualified and follow strict safety standards and quality control. WHO and UNICEF promote vaccine security by working with manufacturers to ensure there is a reliable supply of quality, affordable vaccines, and with governments to assess their vaccine requirements.
 
“UNICEF has a key role in vaccine procurement and procuring immunization supplies on behalf of around 100 countries annually,” said Yukie Mokuo, UNICEF representative in Lebanon. “For the past 25 years UNICEF has brought quality vaccine to the Ministry of Public health to vaccinate all children in Lebanon. Parents and communities are urged to take part in the upcoming measles vaccination campaign to reach every child.”
 
WHO and UNICEF are working with the ministry of Public Health to support vaccine supply and cold chain management, on-the-ground coordination, operations support and monitoring. WHO and UNICEF are also working with the MOPH to ensure clear communication to mobilize the general public aiming to achieve high turnout of all children under 10 years old for vaccination.
 
Representatives from the Ministry of Public Health, WHO, UNICEF, the Lebanese Pediatric Society regional delagates and the heads of other medical societies, stressed during the meeting on the need for commitment and active participation in the campaign, and the need to urge parents and advise them to give their children the extra dose during the campaign regardless of previous doses and that the vaccines provided by the Ministry of Public Health are safe and effective and that the cold chain in its central warehouse and in primary health care centers are of ideal quality and are subject to safe storage conditions .
 
The second phase of the national immunization campaign will be launched in April 2020 targeting children aged between 6 months to less than 10 years old.  All children will also receive vaccination with bivalent Oral Polio Vaccine. Children will be reached in primary healthcare centers/dispensaries, schools, nurseries and private clinics, as well as in Informal settlements
 
ENDS
 
 
About WHO

WHO is the directing and coordinating authority for health within the United Nations. Our aim is to improve future health prospects for people everywhere. WHO works in coordination with its 194 Member States in six regions, through more than 150 country offices, with a single-minded commitment to improve universal health. Together, we aspire to fight communicable diseases such as influenza or HIV, and noncommunicable diseases such as cancer or heart disease. We help mothers and children to survive and prosper, so that they have every chance of reaching a healthy old age. We monitor the safety of air, food and water, and of medicines and vaccines too. Learn more about us at www.who.int
 
About UNICEF

UNICEF works in some of the world’s toughest places, to reach the world’s most disadvantaged children. Across more than 190 countries and territories, we work for every child, everywhere, to build a better world for everyone. For more information about UNICEF and our work in Lebanon visit https://www.unicef.org/lebanon/
 
Follow UNICEF Lebanon on Twitter, Facebook, Instagram and Youtube
 
 
For more information, please contact:

Ministry of Public Health
Dr. Randa Hamade, randa_ham@hotmail.com , T: +961 3 538 878
 
UNICEF
Blanche Baz, bbaz@unicef.org T. +961 03331874
 
WHO
Hala Habib, hhabib@who.int , T: +961 3870459
 
    ...
    135
    ...
ATC Name B/G Ingredients Dosage Form Price
B02BD04 OCTANINE F BioHuman Plasma coagulation factor IX, human - 500IU 500IU Injectable freeze dried powder + diluent 31,425,075 L.L
B02BD04 IMMUNINE BioHuman Plasma coagulation factor IX, human - 600IU 600IU Injectable lyophilised powder for solution+diluent 20,506,214 L.L
L03AX16 MOZOBIL B Plerixafor - 20mg/ml 20mg/ml Injectable solution 413,801,327 L.L
L03AX16 REVIXIL 20 G Plerixafor - 20mg/ml 20mg/ml Injectable solution 248,280,900 L.L
J07AL02 PNEUMOSIL (10-VALENT) G Pneumococcal polysaccharide conjugate vaccine (adsorbed) - Injectable suspension 3,386,483 L.L
J07AL02 VAXNEUVANCE B Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 22F, 23F,33F (2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg) Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate adjuvant - Injectable suspension 6,988,413 L.L
J07AL02 PREVENAR 20 B Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F,8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F,22F, 23F, 33F (2.2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein (approximately 51mcg) adsorbed on aluminium phosphate (0.125mg aluminium) - Injectable suspension 7,415,107 L.L
L01FX14 POLIVY BioHuman Polatuzumab vedotin - 140mg 140mg Injectable powder for concentrate for solution 1,146,496,418 L.L
C05BB02 AETHOXYSKLEROL B Polidocanol (Lauromacrogol 400) - 0.5% 0.5% Injectable solution 1,441,943 L.L
C05BB02 AETHOXYSKLEROL B Polidocanol (Lauromacrogol 400) - 1% 1% Injectable solution 1,732,213 L.L
C05BB02 AETHOXYSKLEROL B Polidocanol (Lauromacrogol 400) - 3% 3% Injectable solution 2,576,146 L.L
J07BF03 POLIOMYELITIS VACCINE INACTIVATED B Poliomyelitis virus type 1 inactivated - 40D.U, Poliomyelitis virus type 2 inactivated - 8D.U, Poliomyelitis virus type 3 inactivated - 32D.U Injectable suspension 1,206,771 L.L
J07CA06 PENTAXIM B Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen (Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg, Tetanus toxoid (Prefilled syringe) - ?40IU, Diphtheria toxoid (Prefilled syringe) - ?30IU, H. Influenza type b polysaccharide(Vial) - 10mcg Injectable dry powder+suspension 2,558,676 L.L
J07CA06 INFANRIX IPV + HIB B Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen(Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg, Tetanus toxoid (Prefilled syringe) - ?40IU, Diphtheria toxoid (Prefilled syringe) - ?30IU, H. Influenza type b polysaccharide(Vial) - 10mcg Injectable dry powder+suspension 3,014,239 L.L
J07AL02 PREVENAR 13 B Polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 23F (2.2mcg)Polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate (0.125mg aluminium) - Injectable suspension 6,352,343 L.L
J07AL02 SYNFLORIX B Polysaccharide from each of 10 capsular types of pneumococcus (conjugated to carrier proteins) adsorbed onto aluminium phosphate - 1mcg/0.5ml, Polysaccharide of serotypes 41,2, 18C1,3 and 19F1,4 - 3mcg/0.5ml, 1 adsorbed onto aluminium phosphate - 0.5mg Al3+, 2 conjugated to protein D (derived from NTHi) carrier protein - ~ 13mcg, 3 conjugated to tetanos toxoid carrier protein - ~ 8mcg, 4 conjugated to diphteria toxoid carrier protein - ~ 5mcg Injectable suspension 4,675,228 L.L
J07AH08 NIMENRIX B Polysaccharide of Neisseria meningitidis (serogroups A, C, Y and W-135) conjugated - 5mcg/0.5ml, Tetanus toxoid carrier protein - 44mcg/0.5ml Injectable lyophilised powder for solution+diluent 4,483,059 L.L
J07AL01 PNEUMOVAX 23 B Polysaccharides from each of 23 capsular types of Streptococcus pneumoniae - 25mcgx23serotypes/0.5ml Injectable solution 2,378,601 L.L
L04AX06 IMNOVID B Pomalidomide - 2mg 2mg Capsule, hard 407,188,707 L.L
L04AX06 IMNOVID B Pomalidomide - 4mg 4mg Capsule, hard 417,741,356 L.L
L04AX06 IMNOVID B Pomalidomide - 4mg 4mg Capsule, hard L.L
L01EA05 ICLUSIG B Ponatinib - 15mg 15mg Tablet, film coated 103,555,839 L.L
L01EA05 ICLUSIG B Ponatinib - 45mg 45mg Tablet, film coated 207,092,651 L.L
J02AC04 NOXAFIL B Posaconazole - 100mg 100mg Tablet, gastroresistant 62,027,714 L.L
A06AD65 MOVICOL B Potassium chloride - 0.0466g, Sodium chloride - 0.3507g, Sodium bicarbonate - 0.1785g, Macrogol 3350 - 13.125g Powder for solution 853,340 L.L
B05XA01 CHLORURE DE POTASSIUM PROAMP G Potassium chloride - 0.0746g/ml 0.0746g/ml Injectable concentrated solution 1,252,461 L.L
B05BB02 HI-SODIUM INJECTION WITH POTASSIUM G Potassium chloride - 0.149g/100ml, Sodium dihydrogenophosphate - 0.137g/100ml, Sodium lactate (anhydre) - 0.223g/100ml, Sodium chloride - 0.175g/100ml, Dextrose monohydrate - 5g/100ml Injectable solution 165,727 L.L
B05BB02 LO-SODIUM WITH POTASSIUM INJECTION G Potassium chloride - 0.149g/100ml, Sodium dihydrogenophosphate - 0.137g/100ml, Sodium lactate - 0.223g/100ml, Sodium chloride - 0.0585g/100ml, Dextrose monohydrate - 5g/100ml Injectable solution 165,727 L.L
A06AD65 FORTRANS POUDRE POUR SOLUTION BUVABLE B Potassium chloride - 0.750g, Sodium chloride - 1460g, Sodium bicarbonate - 1680g, Sodium sulfate anhydrous - 5700g, Macrogol 4000 - 64.000g Powder for solution 927,251 L.L
A12BA01 EURO-K G Potassium chloride - 1.5g 1.5g Tablet, sustained release 573,821 L.L
    ...
    135
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025